Abstract

Recent studies in animal models and humans show that long non-coding RNAs (lncRNAs) are involved in the development of atherosclerosis, which contributes to the pathological foundation of coronary artery disease (CAD). LncRNAs in plasma and serum have been considered as promising novel biomarkers for diagnosis and prognosis of cardiovascular diseases, especially CAD. We here measured the circulating levels of 8 individual lncRNAs which are known to be relevant to atherosclerosis in the plasma samples from 300 patients with CAD and 180 control subjects by using quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) methods. We found that the plasma level of H19 and long intergenic non-coding RNA predicting cardiac remodeling (LIPCAR) were significantly increased in patients with CAD. The area under the receiver operating characteristic curve was 0.631 for H19 and 0.722 for LIPCAR. Multivariate logistic regression analyses indicated that plasma H19 and LIPCAR were independent predictors for CAD, even after adjustment for traditional cardiovascular risk factors. Further studies identified that plasma levels of H19 and LIPCAR were also increased in CAD patients with heart failure compared to those with normal cardiac function. Taken together, our results suggest that increased plasma levels of H19 and LIPCAR are associated with increased risk of CAD and may be considered as novel biomarkers for CAD.

Highlights

  • Coronary artery disease (CAD) remains one of the major causes of mortality and morbidity in many countries, including China[1]

  • We examined plasma levels of eight cardiac-related or atherosclerosis-related long non-coding RNAs (lncRNAs), including H19, long intergenic non-coding RNA predicting cardiac remodeling (LIPCAR), APOA1-AS, TNFα and hnRNPL related immunoregulatory LincRNA (THRIL), highly upregulated in liver cancer (HULC), SLC26A4-AS1, LincRNA-Cox[2], LincRNA-p2111–15, 19–22, in patients with angiographically demonstrated coronary artery disease (CAD) to investigate the possibility of these circulating lncRNAs as novel biomarkers for CAD

  • The CAD group consists of 81 patients with stable angina pectoris (SAP), 189 patients with unstable angina pectoris (UAP), and 30 patients with acute myocardial infarction (AMI)

Read more

Summary

Introduction

Coronary artery disease (CAD) remains one of the major causes of mortality and morbidity in many countries, including China[1]. LncRNAs play crucial roles in chromatin modification, imprinting, cell differentiation and proliferation, transcription, translation and other important biological processes[5]. Non-coding RNAs, including microRNAs and lncRNAs, in plasma and serum have been considered as promising novel biomarkers for diagnosis and prognosis of cardiovascular diseases[17]. We examined plasma levels of eight cardiac-related or atherosclerosis-related lncRNAs, including H19, long intergenic non-coding RNA predicting cardiac remodeling (LIPCAR), APOA1-AS, THRIL, HULC, SLC26A4-AS1, LincRNA-Cox[2], LincRNA-p2111–15, 19–22, in patients with angiographically demonstrated CAD to investigate the possibility of these circulating lncRNAs as novel biomarkers for CAD

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call